# A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD

> **NCT06643078** · PHASE3 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 487 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** HL231 Solution for Inhalation
- **DRUG:** Ultibro 110μg/50 μg

## Key facts

- **NCT ID:** NCT06643078
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-11
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-12-05
- **Target enrollment:** 487 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643078, "A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06643078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*